Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TWIST BIOSCIENCE CORPORATION

(TWST)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Twist Bioscience : Ships RNA Reference Controls for SARS-CoV-2 Variants

07/22/2021 | 10:09am EDT


© MT Newswires 2021
All news about TWIST BIOSCIENCE CORPORATION
09/14TWIST BIOSCIENCE : to Deliver Synthetic RNA Controls for Delta Plus Variants of ..
MT
09/14TWIST BIOSCIENCE : Continues Commitment to Deliver Synthetic RNA Controls, now t..
BU
09/14INSIDER SELL : Twist Bioscience
MT
09/14Twist Bioscience Continues Commitment to Deliver Synthetic RNA Controls, now ..
CI
09/13RENREN : Names Chris Palmer Chief Financial Officer
MT
09/13ADICET BIO : Teams Up With Twist Bioscience to Boost Discovery of Cancer Therapi..
MT
09/10TWIST BIOSCIENCE : Barclays Reiterates Twist Bioscience Overweight Rating, $140 ..
MT
09/09TWIST BIOSCIENCE : Boehringer Ingelheim Collaborate on Therapeutic Antibody Disc..
MT
09/09Boehringer Ingelheim International Gmbh and Twist Bioscience Corporation Anno..
CI
09/08TWIST BIOSCIENCE : to Present at Baird 2021 Global Healthcare Conference
BU
More news
Analyst Recommendations on TWIST BIOSCIENCE CORPORATION
More recommendations
Financials (USD)
Sales 2021 131 M - -
Net income 2021 -151 M - -
Net cash 2021 225 M - -
P/E ratio 2021 -38,7x
Yield 2021 -
Capitalization 6 001 M 6 001 M -
EV / Sales 2021 44,1x
EV / Sales 2022 34,1x
Nbr of Employees 525
Free-Float 90,9%
Chart TWIST BIOSCIENCE CORPORATION
Duration : Period :
Twist Bioscience Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TWIST BIOSCIENCE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 121,74 $
Average target price 119,33 $
Spread / Average Target -1,98%
EPS Revisions
Managers and Directors
Emily Marine Leproust Chairman, President & Chief Executive Officer
James M. Thorburn Chief Financial Officer
Aaron K. Sato Chief Scientific Officer
Siyuan Chen Chief Technology Officer
Patrick Weiss Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
TWIST BIOSCIENCE CORPORATION-19.41%5 613
CSL LIMITED9.25%102 325
WUXI BIOLOGICS (CAYMAN) INC.19.75%63 410
SAMSUNG BIOLOGICS CO.,LTD.12.95%51 545
BIOGEN INC.22.20%44 664
ALEXION PHARMACEUTICALS, INC.0.00%40 336